A. E. Eskazan, "Imatinib mesylate in the management of chemotherapy-induced pulmonary toxicity: a double-edged sword.," Acta oncologica (Stockholm, Sweden) , vol.58, pp.123-124, 2019
Eskazan, A. E. 2019. Imatinib mesylate in the management of chemotherapy-induced pulmonary toxicity: a double-edged sword.. Acta oncologica (Stockholm, Sweden) , vol.58 , 123-124.
Eskazan, A. E., (2019). Imatinib mesylate in the management of chemotherapy-induced pulmonary toxicity: a double-edged sword.. Acta oncologica (Stockholm, Sweden) , vol.58, 123-124.
Eskazan, Ahmet. "Imatinib mesylate in the management of chemotherapy-induced pulmonary toxicity: a double-edged sword.," Acta oncologica (Stockholm, Sweden) , vol.58, 123-124, 2019
Eskazan, Ahmet E. . "Imatinib mesylate in the management of chemotherapy-induced pulmonary toxicity: a double-edged sword.." Acta oncologica (Stockholm, Sweden) , vol.58, pp.123-124, 2019
Eskazan, A. E. (2019) . "Imatinib mesylate in the management of chemotherapy-induced pulmonary toxicity: a double-edged sword.." Acta oncologica (Stockholm, Sweden) , vol.58, pp.123-124.
@article{article, author={Ahmet Emre EŞKAZAN}, title={Imatinib mesylate in the management of chemotherapy-induced pulmonary toxicity: a double-edged sword.}, journal={Acta oncologica (Stockholm, Sweden)}, year=2019, pages={123-124} }